Non-Stimulant ADHD Medications: Complete Guide

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or a prescription recommendation. All medication decisions must be made by you and your licensed healthcare provider based on your individual medical history and circumstances. The dosing details cited are drawn from FDA prescribing information and the NICE NG87 guideline; your prescriber may follow a different plan appropriate to your specific needs.

---

How long do non-stimulant ADHD medications take to work?

Non-stimulant ADHD medications build up over weeks rather than hours. Some people notice early changes in the first one or two weeks, and the effect can keep growing for a month or more, while a stimulant works on the day you take it. Here is what the prescribing information and the main trials show [2][3][4][5][6][7][8][9][15]:

Side effects such as nausea, tiredness or dizziness can show up before any benefit does. How long to stay on a dose before judging it, and when to change or stop, are decisions for your prescriber.

---

When most people hear "ADHD medication," they think of stimulants like Adderall, Vyvanse and Ritalin. That makes sense: guidelines such as NICE NG87 recommend a stimulant (methylphenidate or lisdexamfetamine) as the first medicine to try [12]. But stimulants don't suit everyone.

Non-stimulant ADHD medications get much less attention. They don't produce the same-day "click" that stimulants do, and they're seldom the first thing a prescriber reaches for. NICE lists atomoxetine (and guanfacine for children and young people) as the next option when stimulants can't be tolerated or haven't worked after adequate trials [12]. For some people they end up being the better fit.

This guide covers five non-stimulant options used for ADHD in the US and UK: Strattera (atomoxetine), Intuniv (guanfacine ER), Qelbree (viloxazine), Wellbutrin (bupropion) used off-label, and clonidine ER. For each, we cover what the label says about how it works, dosing, onset, side effects, and the points worth raising with your prescriber.

---

Why consider non-stimulants at all?

It helps to understand the basic difference in approach.

Stimulants raise dopamine and norepinephrine quickly, and their effect starts and wears off within the day [15]. Atomoxetine and viloxazine block norepinephrine reuptake, guanfacine and clonidine act on alpha-2 receptors, and bupropion is a weak inhibitor of norepinephrine and dopamine reuptake [2][4][5][7][9]. None of them is a controlled substance, and they build their effect over days to weeks instead of hours.

---

Strattera (atomoxetine)

Strattera was first approved in the US in 2002 [2], and for many years it was the only non-stimulant with an FDA label for adults with ADHD. Qelbree's label now covers adults too [5].

Mechanism of action

Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). The label says its exact mechanism in ADHD is unknown but is thought to come from blocking the norepinephrine transporter [2]. In rat studies it raised norepinephrine and dopamine in the prefrontal cortex but did not raise dopamine in the striatum or nucleus accumbens, the reward area that stimulants affect [13]. The label reports no stimulant or euphoriant effects in an abuse-potential study [2].

Dosing and what to track

Atomoxetine comes in several capsule strengths and can be taken once in the morning or split into morning and late-afternoon doses [2]. Your prescriber chooses the starting dose, the pace, and any change, based on your weight, other medications, and how you respond. Titrate does not recommend doses.

• Log: dose time, nausea, sleep, appetite, mood, and a daily focus rating.
• Discuss: whether splitting the dose would help if side effects are bothering you.

Onset timeline

This is the most important thing to understand about atomoxetine: it builds slowly. A review of the trial data found it can start working within 1–2 weeks, with the response continuing to grow for up to 24 weeks or longer [3]. Many people expect stimulant-like speed and are disappointed in the first weeks. For what each of those weeks usually feels like, see the Strattera titration schedule, week by week.

Common side effects

In the label's adult trials, the most common side effects compared with placebo were [2]:

• Nausea: 26% vs 6%.
• Dry mouth: 20% vs 5%.
• Decreased appetite: 16% vs 3%.
• Insomnia: 15% vs 8%.
• Fatigue and sleepiness: fatigue 10% vs 6%, somnolence 8% vs 5%. If drowsiness is a problem, ask your prescriber whether timing the dose differently could help.
• Sexual side effects: erectile dysfunction in 8% of men vs 1% on placebo.
• Heart rate and blood pressure: both can rise, and the rise is larger in people who process the drug slowly (CYP2D6 poor metabolizers).

Contraindications

The label lists these [2]:

• MAOIs (monoamine oxidase inhibitors): not together, or within 14 days of stopping an MAOI.
• Narrow-angle glaucoma: atomoxetine was linked to pupil dilation in trials.
• Pheochromocytoma, current or past: serious rises in blood pressure and heart rhythm problems have been reported.
• Severe heart or blood vessel disorders that would get worse with a meaningful rise in blood pressure or heart rate.
• Known allergy to atomoxetine.

CYP2D6 poor metabolizers, and people taking strong CYP2D6 inhibitors such as fluoxetine or paroxetine, have much higher blood levels, so the label suggests a longer gap between dose steps for them [2].

Who is a good candidate?

---

Intuniv (guanfacine ER)

Intuniv is the extended-release form of guanfacine, an alpha-2A adrenergic receptor agonist first approved as a blood pressure medicine. The Intuniv label covers ADHD in children and teens aged 6 to 17, either alone or added to a stimulant [4]. It is used off-label in adults, and NICE says guanfacine should only be offered to adults after advice from a specialist ADHD service [12].

Mechanism of action

Guanfacine works differently from both stimulants and atomoxetine. It stimulates alpha-2A receptors, with 15 to 20 times more affinity for that subtype than for the alpha-2B or 2C subtypes [4]. The label says its mechanism in ADHD is not known [4]; one leading hypothesis is that it improves how prefrontal cortex circuits handle attention and impulse control [14].

Dosing and what to track

Guanfacine ER comes in several tablet strengths and must be swallowed whole (no crushing, chewing, or splitting). The label says it should not be taken with a high-fat meal, because that raises exposure [4]. Your prescriber decides the starting dose, the pace of any change, and where to stop.

• Log: dose time, sleepiness, dizziness, energy, and a daily focus rating.
• Discuss: whether morning or evening dosing fits your day (the label allows either), and what to do about missed doses.

Onset timeline

The label starts at 1 mg a day and raises the dose by no more than 1 mg each week [4], so simply reaching a target dose can take several weeks. The label does not give a single onset figure. Ask your prescriber how long they plan to wait at each step before judging the effect.

Common side effects

In the label's fixed-dose trials in children and teens [4]:

• Sleepiness: 38% across all doses vs 11% on placebo, rising with dose.
• Fatigue: 14% vs 3%.
• Low blood pressure: 7% vs 3%. Dizziness on standing and fainting can happen, and the label advises checking heart rate and blood pressure before starting and after dose increases.
• Dizziness: 6% vs 4%.
• Nausea and dry mouth: 6% vs 2% and 4% vs 1%.

Contraindications

The only listed contraindication is an allergy to guanfacine [4]. The label's warnings cover:

• Low blood pressure, slow heart rate and fainting: extra caution with a history of these.
• Heart conduction problems, especially with other drugs that slow the heart.
• Sedating drugs: added sleepiness with other central nervous system depressants.
• CYP3A4 inhibitors or inducers (for example ketoconazole or carbamazepine): the label adjusts the dose for these.
• Stopping suddenly: can cause rebound high blood pressure, so the label tapers the dose.

Who is a good candidate?

---

Qelbree (viloxazine)

Qelbree is the newest non-stimulant here. It was first approved in 2021 and its label now covers adults and children from age 6 [5]. It is a norepinephrine reuptake inhibitor with a different chemical structure from atomoxetine.

Mechanism of action

The label says viloxazine's mechanism in ADHD is unclear but is thought to involve blocking norepinephrine reuptake. It also binds the serotonin 5-HT2C receptor as a partial agonist [5]. No head-to-head trial with atomoxetine has shown whether this changes the side-effect profile.

Dosing and what to track

Viloxazine comes as extended-release capsules that can be swallowed whole or opened and sprinkled on applesauce or pudding [5]. Your prescriber chooses the starting dose and any later change, and the label's plan differs for children, adolescents, and adults. Titrate does not recommend doses.

• Log: dose time, sleep, appetite, mood, and a daily focus rating.
• Discuss: any change in mood or sleep, and how the medicine fits with your other prescriptions.

Onset timeline

In the adult trial, many effects were already significant by week 2, and the trial ran for 6 weeks in total [6]. The label raises the dose in weekly steps [5].

Common side effects

• Insomnia: the most common side effect in adults, 23% vs 7% on placebo [5]. In children, sleepiness was more common (16% vs 4%).
• Headache: 17% vs 7% in adults.
• Nausea and fatigue: each 12% vs 3% in adults.
• Dry mouth and decreased appetite: each 10% vs 2–3% in adults.
• Heart rate and blood pressure: the label advises checking both before starting, after dose increases, and periodically [5].

Contraindications

The label lists two [5]:

• MAOIs: not together, or within 14 days of stopping one, because of the risk of a hypertensive crisis.
• Certain CYP1A2 substrates: medicines that are sensitive to CYP1A2 or have a narrow safety margin, because viloxazine raises their levels.

Qelbree also carries an FDA boxed warning for suicidal thoughts and behaviors. Anyone taking it should be watched for worsening mood or new suicidal thoughts, especially early on and after dose changes [5].

Who is a good candidate?

---

Wellbutrin (bupropion) — off-label use

Wellbutrin (bupropion) is not FDA-approved for ADHD; its XL label covers depression and seasonal affective disorder [7]. It is prescribed off-label for ADHD, particularly when depression is also present.

Mechanism of action

The label says bupropion's mechanism is unknown, and describes it as a relatively weak inhibitor of norepinephrine and dopamine reuptake that does not affect serotonin reuptake [7]. That dual action on norepinephrine and dopamine sets it apart from the other non-stimulants here.

Dosing and what to track

Bupropion comes in immediate-release, sustained-release, and extended-release (XL) forms. The XL form is taken once daily in the morning, and the label raises the dose gradually to lower seizure risk [7]. Your prescriber chooses the formulation, the starting dose, and any change. Titrate does not recommend doses.

• Log: dose time, sleep, appetite, tremor, anxiety, and a daily focus rating.
• Discuss: your seizure and eating-disorder history, alcohol use, and any other medicines, because these affect whether bupropion is appropriate.

Onset timeline

In an 8-week trial of bupropion XL in adults with ADHD, 53% responded vs 31% on placebo, and the difference was already significant at week 2 [8]. In a large network meta-analysis of adult trials, bupropion's effect size was similar to atomoxetine's and smaller than that of the stimulants [1].

Common side effects

From the Wellbutrin XL label's depression trials [7]:

• Dry mouth and headache: the most frequent, for example dry mouth in 17–24% vs 7% on placebo.
• Nausea: 13–18% vs 8%.
• Insomnia: 11–16% vs 6%.
• Dizziness, tremor, anxiety and agitation: less common but more frequent than on placebo.
• Seizures: the risk rises with dose, which is why the dose is raised slowly and capped.
• Blood pressure: can rise, so the label advises checking it.

Contraindications

The label lists [7]:

• Seizure disorder.
• Current or past bulimia or anorexia nervosa, because seizures were more common in these patients.
• Abrupt stopping of alcohol, benzodiazepines, barbiturates or antiepileptic drugs.
• MAOIs, together or within 14 days.

The label also names severe head injury, CNS tumour or infection, and severe stroke as conditions that raise seizure risk.

Who is a good candidate?

---

Clonidine ER (Kapvay)

Clonidine ER (sold as Kapvay and as generic clonidine extended-release tablets) is an alpha-2 adrenergic agonist like guanfacine, but less selective for the alpha-2A subtype [4][9]. Its label covers ADHD in children and teens aged 6 to 17, alone or added to a stimulant [9]. NICE says it should only be considered for under-18s after advice from a specialist ADHD service [12].

Mechanism of action

Clonidine stimulates alpha-2 adrenergic receptors in the brain. It is not a stimulant, and the label says its mechanism in ADHD is not known [9].

Dosing and what to track

Clonidine ER comes as tablets that must be swallowed whole. The label starts at bedtime, raises the dose weekly, and splits it into morning and bedtime doses, with an equal or larger dose at bedtime [9]. Any change is made by the prescriber. Titrate does not recommend doses.

• Log: dose times, sleepiness, dizziness, and pulse or blood pressure readings if your prescriber has asked for them.
• Discuss: how to stop safely, since the label tapers the dose to avoid a rebound rise in blood pressure. Talk to your prescriber before stopping.

Onset timeline

The label raises the dose in weekly steps, and the controlled trials measured the effect at week 5 [9][11]. It gives no single onset figure.

Common side effects

• Sleepiness: the most prominent effect. In a 5-week trial in children, 31–38% reported somnolence vs 4% on placebo; added to a stimulant, 19% vs 7% [9].
• Low blood pressure and slow heart rate: dose-related, so the label advises checking heart rate and blood pressure before starting, after dose increases, and periodically.
• Rebound high blood pressure: if clonidine is stopped suddenly, which is why the label tapers it.

Contraindications

The only listed contraindication is an allergy to clonidine [9]. The label's warnings cover:

• Low blood pressure, slow heart rate, fainting, heart block or other heart and blood vessel disease.
• Other drugs that lower blood pressure or heart rate, or are sedating, which can add to these effects.
• Kidney impairment: the label says the dose must be adjusted to the degree of impairment.

Who is a good candidate?

---

Comparison table: non-stimulants at a glance

---

When to combine non-stimulants with stimulants

Some prescribers use combination therapy: a stimulant for daytime symptoms plus a non-stimulant, most often guanfacine ER or clonidine ER, whose labels both cover use alongside a stimulant [4][9].

The evidence for this approach:

• Guanfacine ER + stimulant: in a 9-week controlled trial in children and teens who had only a partial response to their stimulant, adding guanfacine ER improved ADHD symptoms more than adding placebo, with no new safety signals [10].
• Clonidine ER + stimulant: in a controlled trial in children and teens with a partial response to stimulants, adding clonidine ER improved symptom scores at week 5 compared with placebo [11].
• Atomoxetine + stimulant: less studied, and not covered by the Strattera label.

Worth knowing: combining medicines can add to cardiovascular effects. Ask your prescriber how often they want blood pressure and heart rate checked during combination therapy, and whether they plan to change one medicine at a time.

---

Non-stimulant titration: the 4–8 week challenge

The hardest part of non-stimulant treatment is often patience. The stimulant experience, with fast feedback and a same-day effect, does not prepare anyone for a slower timeline.

Here's what to expect:

• Weeks 1–2: side effects such as nausea, tiredness or dizziness may show up before any clear benefit. Some people notice early improvement, since the atomoxetine, viloxazine and bupropion trials all showed changes within this window [3][6][8]. If side effects are severe, contact your prescriber.
• Weeks 3–4: dose steps are often still under way, especially for guanfacine and clonidine, which go up weekly [4][9].
• Weeks 5–8 and beyond: the picture usually becomes clearer, and atomoxetine's effect can keep growing for months [3]. When to judge a dose and whether to change it is your prescriber's call.

Structured logging of side effects, sleep and daily function gives you and your prescriber something solid to look at, instead of trying to remember how week 3 felt.

---

FAQ

Q: How long do non-stimulant ADHD medications take to work? Longer than stimulants, which work on the day you take them. Atomoxetine can start helping within 1–2 weeks and keeps building for months, viloxazine and bupropion XL showed significant changes by week 2 in adult trials, and guanfacine ER and clonidine ER are raised in weekly steps, so reaching the target dose takes several weeks. Side effects often show up before the benefit.

Q: Do non-stimulants work as well as stimulants? On average, no. In a large network meta-analysis, the effect size in adults was about 0.79 for amphetamines and 0.49 for methylphenidate, against about 0.45 for atomoxetine and 0.46 for bupropion [1]. But averages don't decide what works for one person, and for someone who can't tolerate stimulants a non-stimulant may be the better fit.

Q: Can you take a non-stimulant and a stimulant together? Some combinations are studied and labelled. The Intuniv and clonidine ER labels both cover use alongside a stimulant, and controlled trials showed added benefit [10][11]. Only combine medicines under your prescriber's care.

Q: Do non-stimulants show up on drug tests? The Wellbutrin XL label says bupropion can cause false-positive urine test results for amphetamines [7]. The Strattera, Intuniv, Qelbree and clonidine ER labels list no such drug-test interaction. If you are being tested, tell the testing service what you take, since a confirmatory test can tell the drugs apart.

Q: Which non-stimulant is best for sleep? That depends on your situation, so it's a question for your prescriber. In the labels, sleepiness was the most common side effect of clonidine ER and guanfacine ER, while insomnia was reported more often than on placebo with atomoxetine, viloxazine and bupropion [2][4][5][7][9]. NICE mentions clonidine, with specialist advice, for children with ADHD and sleep problems [12].

Q: Can I stop non-stimulants suddenly? Not without talking to your prescriber. The Intuniv and clonidine ER labels say to taper the dose because stopping suddenly can cause rebound high blood pressure and a faster heart rate [4][9]. The Strattera label says no taper is needed [2]. Ask your prescriber about the others.

Q: Are non-stimulants safe in pregnancy? The data are limited. The Strattera, Intuniv, Qelbree and clonidine ER labels each point to a pregnancy exposure registry, and bupropion has one for antidepressants [2][4][5][7][9]. The Qelbree label says it may cause harm in pregnancy based on animal studies and should be stopped when pregnancy is recognized unless the benefit outweighs the risk [5]. Talk to your prescriber before you try to conceive.

Q: Why don't doctors prescribe non-stimulants first? UK guidance from NICE recommends methylphenidate (for children) or lisdexamfetamine or methylphenidate (for adults) as the first medicine, and offers atomoxetine, or guanfacine for children and young people, when stimulants can't be tolerated or haven't worked after separate 6-week trials [12]. Stimulants also have larger average effects in trials [1].

Q: What's the success rate of non-stimulants? It varies by drug and by how response is defined. In the adult bupropion XL trial, 53% responded vs 31% on placebo [8]. A review of atomoxetine data found its responder rates similar to methylphenidate's in the studies it covered [3]. If one non-stimulant doesn't work, your prescriber may suggest another.

---

Key takeaways

1. Non-stimulant ADHD medications are different, not a lesser version. They trade the fast effect of stimulants for a steadier build-up, no controlled-substance status, and side-effect profiles that suit different people.
2. The biggest hurdle is the slow start. Benefits build over weeks, and side effects can come first. Structured tracking helps you and your prescriber see the trend.
3. Each non-stimulant has a distinct profile. Atomoxetine is NICE's main non-stimulant for adults. Guanfacine and clonidine are alpha-2 agonists whose most common side effect is sleepiness. Bupropion is approved for depression and used off-label for ADHD. Viloxazine is the newest option, with insomnia as its most common adult side effect.
4. Combining a stimulant with guanfacine ER or clonidine ER is labelled and trial-tested in children and teens.
5. Dose changes follow each label's own pace, from every few days for atomoxetine to weekly for the others. How long to give each step is a question for your prescriber.

---

Track your non-stimulant titration with Titrate

Non-stimulant titration is a longer, quieter process than stimulant titration, with weeks of small changes that are easy to misremember at a doctor's appointment. A structured tracker helps you see the signal through the noise: sleep quality, side effect intensity, functional improvement, and mood, logged daily and lined up with dose changes.

The Titrate app is built for exactly this. One-tap daily check-ins, structured side effect logging, and a shareable report that shows your prescriber what happened over the whole trial, not just what you remember from the morning of your appointment.

→ Start tracking your non-stimulant titration ← → Learn more about what your prescriber sees ←

---

References

1. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
2. Strattera (atomoxetine) — FDA Prescribing Information. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb
3. Clemow DB, Bushe CJ. Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol. 2015;29(12):1221–1230.
4. Intuniv (guanfacine extended-release) — FDA Prescribing Information. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b972af81-3a37-40be-9fe1-3ddf59852528
5. Qelbree (viloxazine extended-release) — FDA Prescribing Information. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a
6. Nasser A, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022;36(8):897–915.
7. Wellbutrin XL (bupropion extended-release) — FDA Prescribing Information. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a435da9d-f6e8-4ddc-897d-8cd2bf777b21
8. Wilens TE, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793–801.
9. Clonidine hydrochloride extended-release tablets (ADHD) — FDA Prescribing Information. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0100c70d-7fde-46a1-8374-940550a27e43
10. Wilens TE, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.
11. Kollins SH, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–e1413.
12. NICE. Attention deficit hyperactivity disorder: diagnosis and management (NG87). https://www.nice.org.uk/guidance/ng87
13. Bymaster FP, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711.
14. Arnsten AF, Scahill L, Findling RL. α2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17(4):393–406.
15. Vyvanse (lisdexamfetamine) — FDA Prescribing Information. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad

---

This article is for educational purposes only. It does not constitute medical advice. Always consult your licensed healthcare provider about medication decisions.